Can-Fite BioPharma (NYSE:CANF) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report issued to clients and investors on Tuesday. The brokerage set a “hold” rating on the stock.

Can-Fite BioPharma Stock Down 0.5 %

NYSE:CANF opened at $1.97 on Tuesday. Can-Fite BioPharma has a 12-month low of $1.71 and a 12-month high of $3.33. The stock’s fifty day simple moving average is $2.15 and its 200-day simple moving average is $2.11. The firm has a market capitalization of $6.97 million, a P/E ratio of -1.10 and a beta of 1.53.

Can-Fite BioPharma (NYSE:CANF) last announced its quarterly earnings results on Thursday, March 28th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). Can-Fite BioPharma had a negative net margin of 1,027.46% and a negative return on equity of 113.75%. The firm had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.20 million. As a group, equities research analysts expect that Can-Fite BioPharma will post -0.03 earnings per share for the current year.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. Schechter Investment Advisors LLC bought a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 20,077 shares of the company’s stock, valued at approximately $44,000. Schechter Investment Advisors LLC owned approximately 0.57% of Can-Fite BioPharma as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.